Merge Talks Between The EVERY Co and Onego Bio
Alt-egg startups The EVERY Company and Onego Bio had been discussing a merger to create a new company with a valuation of $400m before talks fell apart.
Details of the talks were shared in an October 28 legal filing by The EVERY Co, which urged a court in Wisconsin to toss a lawsuit from Onego Bio seeking to invalidate one of EVERY’s patents.
Patent Dispute
The IP at issue covers the production of ovalbumin, the primary protein in egg white, via precision fermentation.
- The EVERY Co uses yeast (Komagataella phaffii) as its host microorganism.
- Onego Bio uses fungus (Trichoderma reesei).
The dispute centers on whether Onego is infringing a “foundational” patent (‘784) from The EVERY Co covering ovalbumin expression in a range of hosts.
Author's summary: Merger talks between The EVERY Co and Onego Bio failed due to patent disputes.
More News
- OpenAI’s ChatGPT Atlas: A Bold Browser That Could Shake Up Google
- Quick start, steady goaltending propel Sharks to first home win of season
- Bravo Network Cashes in on Paid Apostasy and Anti‑LDS Bigotry
- Sharks Turn Back Clock, Rock Devils 5-2
- Pascendi and the Pope Who Didn't 'Trust the Science'
- ‘Avatar: The Last Airbender,’ comes to life through on-stage orchestra
- When An Infant Spoke and the Apostles Stayed Silent: A Lesson for the Modern Age
- Where to Find Arc Raiders Supply Drops and Call Station to Complete 'A Better Use' Quest